Tango Therapeutics price target raised to $21 from $14 at B. Riley

B. Riley raised the firm’s price target on Tango Therapeutics (TNGX) to $21 from $14 and keeps a Buy rating on the shares. Shares have rebounded sharply despite limited new catalysts, with recent strength unlikely driven by its early-stage ERAS collaboration and more likely reflecting read-through from combination data in the PRMT5 space, the analyst tells investors in a research note. The core focus remains vopimetostat’s differentiated safety profile, which could enable higher dosing and stronger efficacy in combinations with RAS inhibitors or chemotherapy, positioning upcoming NSCLC and combo data as key catalysts, the firm says.